Biotech · Private company

Taiho Oncology, Inc.

Track this companyFree. Adds Taiho Oncology, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials2520 recruiting or active

Pipeline programs29From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline29

ASTX030 (cedazuridine + azacitidine)Phase 3 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
AzacitidinePhase 3 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
CedazuridinePhase 3 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
futibatinibPhase 3 · Advanced/Metastatic CancerClinicalTrials.gov · fetched Nov 12, 2026
futibatinib, fulvestrantPhase 3 · Advanced/Metastatic CancerClinicalTrials.gov · fetched Nov 12, 2026
TAS6417Phase 3 · Advanced or Metastatic NSCLS With Exon 20 Insertion MutationClinicalTrials.gov · fetched Nov 12, 2026
TAS6417Phase 3 · Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
VenetoclaxPhase 3 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
5-FUPhase 2 · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal CancerClinicalTrials.gov · fetched Nov 12, 2026
ASTX660Phase 2 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
ASTX727Phase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
ASTX727 LDPhase 2 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
ASTX727 SDPhase 2 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
CisplatinPhase 2 · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal CancerClinicalTrials.gov · fetched Nov 12, 2026
CYP CocktailPhase 2 · Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) MutationsClinicalTrials.gov · fetched Nov 12, 2026
Decitabine and Cedazuridine (ASTX727)Phase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
FutibatinibPhase 2 · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal CancerClinicalTrials.gov · fetched Nov 12, 2026
LeucovorinPhase 2 · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal CancerClinicalTrials.gov · fetched Nov 12, 2026
OxaliplatinPhase 2 · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal CancerClinicalTrials.gov · fetched Nov 12, 2026
PembrolizumabPhase 2 · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal CancerClinicalTrials.gov · fetched Nov 12, 2026
TAS-120Phase 2 · Advanced CholangiocarcinomaClinicalTrials.gov · fetched Nov 12, 2026
TAS6417Phase 2 · Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) MutationsClinicalTrials.gov · fetched Nov 12, 2026
Transporter CocktailPhase 2 · Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) MutationsClinicalTrials.gov · fetched Nov 12, 2026
VenetoclaxPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
ARC-02Phase 1 · B-cell Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Decitabine + CedazuridinePhase 1 · Relapsed/Refractory Peripheral T-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
RituximabPhase 1 · B-cell Non Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
TAS3351Phase 1 · Non-Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
TolinapantPhase 1 · Relapsed/Refractory Peripheral T-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung CancerPHASE2 · NOT_YET_RECRUITING · started Jun 1, 2027ClinicalTrials.gov NCT07229339 · fetched Nov 12, 2026
A Study of ARC-02 in B-cell NHLPHASE1 · RECRUITING · started Jun 22, 2026ClinicalTrials.gov NCT07691606 · fetched Nov 12, 2026
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionPHASE3 · RECRUITING · started Dec 22, 2025ClinicalTrials.gov NCT07128199 · fetched Nov 12, 2026
Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.PHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Oct 1, 2024ClinicalTrials.gov NCT06506955 · fetched Nov 12, 2026
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)PHASE3 · ACTIVE_NOT_RECRUITING · started Dec 18, 2023ClinicalTrials.gov NCT05973773 · fetched Nov 12, 2026
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.PHASE2 · RECRUITING · started Jul 31, 2023ClinicalTrials.gov NCT05967689 · fetched Nov 12, 2026
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid TumorsPHASE2 · ACTIVE_NOT_RECRUITING · started Jul 13, 2023ClinicalTrials.gov NCT05945823 · fetched Nov 12, 2026
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or RearrangementPHASE2 · RECRUITING · started Jul 5, 2023ClinicalTrials.gov NCT05727176 · fetched Nov 12, 2026
A Study of TAS3351 in NSCLC Patients With EGFRmtPHASE1 · TERMINATED · started May 25, 2023ClinicalTrials.gov NCT05765734 · fetched Nov 12, 2026
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)PHASE1 · TERMINATED · started Feb 22, 2023ClinicalTrials.gov NCT05403450 · fetched Nov 12, 2026
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic ImpairmentPHASE1 · RECRUITING · started Dec 23, 2022ClinicalTrials.gov NCT04953910 · fetched Nov 12, 2026
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid LeukemiaPHASE1 · ACTIVE_NOT_RECRUITING · started Oct 28, 2022ClinicalTrials.gov NCT05396859 · fetched Nov 12, 2026
Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal MelanomaPHASE1_PHASE2 · COMPLETED · started Jun 20, 2022ClinicalTrials.gov NCT05089370 · fetched Nov 12, 2026
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell TransplantPHASE1_PHASE2 · RECRUITING · started May 12, 2022ClinicalTrials.gov NCT04742634 · fetched Nov 12, 2026
Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal ImpairmentPHASE1 · RECRUITING · started Dec 15, 2021ClinicalTrials.gov NCT04953897 · fetched Nov 12, 2026
Inqovi Maintenance Therapy in Myeloid NeoplasmsPHASE1 · ACTIVE_NOT_RECRUITING · started Sep 17, 2021ClinicalTrials.gov NCT04980404 · fetched Nov 12, 2026
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Feb 9, 2021ClinicalTrials.gov NCT04657081 · fetched Nov 12, 2026
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)PHASE2_PHASE3 · RECRUITING · started May 21, 2020ClinicalTrials.gov NCT04256317 · fetched Nov 12, 2026
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung CancerPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Oct 31, 2019ClinicalTrials.gov NCT04036682 · fetched Nov 12, 2026
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)PHASE2 · ENROLLING_BY_INVITATION · started Sep 30, 2019ClinicalTrials.gov NCT04093570 · fetched Nov 12, 2026
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDSPHASE1_PHASE2 · COMPLETED · started Jul 27, 2018ClinicalTrials.gov NCT03502668 · fetched Nov 12, 2026
TAS102 in Combination With NAL-IRI in Advanced GI CancersPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jan 30, 2018ClinicalTrials.gov NCT03368963 · fetched Nov 12, 2026
Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal CancerPHASE1_PHASE2 · COMPLETED · started Oct 13, 2017ClinicalTrials.gov NCT03223779 · fetched Nov 12, 2026
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerPHASE2 · RECRUITING · started Mar 14, 2016ClinicalTrials.gov NCT02693535 · fetched Nov 12, 2026
Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and LymphomasPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jul 14, 2015ClinicalTrials.gov NCT02503423 · fetched Nov 12, 2026